Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Stimulant use linked to sudden death in children without heart problems.

Kuehn BM.

JAMA. 2009 Aug 12;302(6):613-4. doi: 10.1001/jama.2009.1115. No abstract available.

PMID:
19671894
2.

Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder.

Ross RG.

Am J Psychiatry. 2006 Jul;163(7):1149-52. No abstract available.

PMID:
16816217
3.

Methylphenidate transdermal system.

Mays DA, Findling R.

J Am Acad Child Adolesc Psychiatry. 2005 Dec;44(12):1223. No abstract available.

PMID:
16292112
4.

Stimulant treatment of ADHD and risk of sudden death in children.

Vitiello B, Towbin K.

Am J Psychiatry. 2009 Sep;166(9):955-7. doi: 10.1176/appi.ajp.2009.09050619. No abstract available.

PMID:
19528196
5.

Quillivant XR--an extended release oral suspension of methylphenidate.

[No authors listed]

Med Lett Drugs Ther. 2013 Feb 4;55(1409):10-1. No abstract available.

PMID:
23381227
6.

ADHD drugs and cardiovascular risk.

Rappley MD, Moore JW, Dokken D.

N Engl J Med. 2006 May 25;354(21):2296-8; author reply 2296-8. No abstract available.

PMID:
16729375
7.

Debate over warnings for ADHD stimulants.

[No authors listed]

Child Health Alert. 2006 Apr;24:1. No abstract available.

PMID:
16673500
8.

Methylphenidate: abuse and addiction.

[No authors listed]

Prescrire Int. 2012 Oct;21(131):241. No abstract available.

PMID:
23189380
9.

[Attitude to questionable cadiac risks in stimulant administration].

Fegert JM, Hebebrand J; Kommission Entwicklungspsychopharmakologie der drei Fachgesellschaften..

Z Kinder Jugendpsychiatr Psychother. 2006 Jul;34(4):295-7. German. No abstract available.

PMID:
16927572
10.

Prevalence and correlates of illicit methylphenidate use among 8th, 10th, and 12th grade students in the United States, 2001.

McCabe SE, Teter CJ, Boyd CJ, Guthrie SK.

J Adolesc Health. 2004 Dec;35(6):501-4.

PMID:
15581530
11.
12.

[Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].

Bange F, Le Heuzey MF, Acquaviva E, Delorme R, Mouren MC.

Arch Pediatr. 2014 Jan;21(1):108-12. doi: 10.1016/j.arcped.2013.11.001. French.

PMID:
24309201
13.

Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?

Killeen MR.

J Child Fam Nurs. 2000 Jan-Feb;3(1):46-8. No abstract available.

PMID:
11022478
14.

Attention-deficit hyperactivity disorder (ADHD) treatment and sudden death.

Besag FM.

Drug Saf. 2009;32(11):1097-100. doi: 10.2165/11530340-000000000-00000. No abstract available.

PMID:
19810781
15.

Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study.

Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ.

J Dev Behav Pediatr. 2006 Feb;27(1):1-10.

PMID:
16511362
16.

Methylphenidate in treatment of adults with Attention-Deficit/Hyperactivity Disorder.

Biederman J, Spencer T.

J Atten Disord. 2002;6 Suppl 1:S101-7.

PMID:
12685524
17.

ADHD drugs and cardiovascular risk.

Nissen SE.

N Engl J Med. 2006 Apr 6;354(14):1445-8. No abstract available.

18.

Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.

Newcorn JH, Donnelly C.

Mt Sinai J Med. 2009 Apr;76(2):198-203. doi: 10.1002/msj.20096. No abstract available.

PMID:
19306385
19.
20.

Letter to the editor: Comment on 'Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder'.

Olders H.

J Pediatr Psychol. 2009 Jan-Feb;34(1):108-9; author reply 110-2. doi: 10.1093/jpepsy/jsn139. No abstract available. Erratum in: J Pediatr Psychol. 2009 May;34(4):452.

Items per page

Supplemental Content

Support Center